Pharmacoeconomic Analysis of Brigatinib versus Alectinib in First‑Line Treatment of Anaplastic Lymphoma Kinase‑Positive Advanced Non‑Small‑Cell Lung Cancer in China

Abstract Introduction Brigatinib and alectinib are anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (ALK-TKIs) approved in China in 2022 and 2018, respectively, for the treatment of patients with ALK-positive, advanced non‑small‑cell lung cancer (NSCLC). The objective of this study is to...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Qingqing Chai, Congling Gu, Luis Hernandez, Yan-Jun Zhang
Format:	Artigo
Jezik:	Inglês
Izdano:	Adis, Springer Healthcare 2025-07-01
Serija:	Oncology and Therapy
Teme:	Anaplastic lymphoma kinase (ALK) Non-small cell lung cancer Brigatinib Pharmacoeconomics Tyrosine kinase inhibitor
Online dostop:	https://doi.org/10.1007/s40487-025-00361-3
Oznake:	Označite Brez oznak, prvi označite!